TG Therapeutics Inc
TGTX
View Detailed Chart
31.980USD
+0.160+0.50%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
9.10BMarket Cap
10.32P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.50%
5 Days
+5.34%
1 Month
+3.50%
6 Months
-9.92%
Year to Date
+7.28%
1 Year
-21.60%
View Detailed Chart
TradingKey Stock Score of TG Therapeutics Inc
Currency: USD Updated: 2026-03-25Key Insights
TG Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.17.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TG Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
TG Therapeutics Inc Highlights
StrengthsRisks
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 163.75% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 616.29M.
Fairly Valued
The company’s latest PE is 10.27, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 103.04M shares, decreasing 14.69% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 35.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.19.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
44.167
Target Price
+46.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
TG Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
TG Therapeutics Inc Info
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Ticker SymbolTGTX
CompanyTG Therapeutics Inc
CEOWeiss (Michael S)
Websitehttps://www.tgtherapeutics.com/
Related Instruments
-2.11%
-1.00%
-0.29%
-2.00%
-0.37%
+1.90%
-0.70%
-0.22%
-1.84%
+1.06%
+0.19%
+1.28%
-1.39%
+0.83%
-0.27%
0.00%
+0.97%
-1.71%
-0.07%
-1.26%Popular Symbols
252.890
+0.270 (+0.11%)
171.240
-7.440 (-4.16%)
68862.240
-112.970 (-0.16%)
273.350
-22.790 (-7.70%)
2062.130
-0.260 (-0.01%)
372.110
-13.840 (-3.59%)
4440.330
+60.270 (+1.38%)
92.959
-0.363 (-0.39%)
1.154
+0.001 (+0.12%)
159.565
-0.222 (-0.14%)
